Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.

[hodgkin lymphoma, classical]

Despite the relative success of chemotherapy for Hodgkin lymphoma (HL ) and systemic anaplastic large cell lymphoma (ALCL ), novel therapeutic agents are needed for refractory or relapsed patients . Targeted immunotherapy has emerged as a novel treatment option for these patients . Although unconjugated anti-cluster of differentiation (CD )30 antibodies showed minimal antitumor activity in early clinical trials , development of antibody-drug conjugates (ADCs ) appears promising . Brentuximab vedotin is an ADC composed of an anti-CD 30 antibody linked to a potent microtubule-disrupting agent monomethyl auristatin E (MMAE ). It has the ability to target CD 30 -positive tumor cells and , once bound to CD 30 , brentuximab vedotin is internalized and MMAE is released to induce cell cycle arrest and apoptosis . In two Phase II trials , objective response was reported in 75 % and 86 % of patients with refractory or relapsed HL and systemic ALCL , respectively , with an acceptable toxicity profile . Based on these studies , the US Food and Drug Administration (FDA ) granted accelerated approval of brentuximab vedotin in August 2011 for the treatment of refractory and relapsed HL and ALCL . We review the key characteristics of brentuximab vedotin , clinical data supporting its therapeutic efficacy , and current ongoing trials to explore its utility in other CD 30 -positive malignancies .

Diseases
Validation

Diseases presenting "early clinical trials" symptom

hodgkin lymphoma, classical

You can validate or delete this automatically detected symptom